# US 2026/0217851 A1 · Compositions that Target CD138 and CD3 and Methods of Making and Using the Same > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 2026/0217851 A1 - Document ID: US20260217851A1 - Status: Published application - Kind: A1 - Application number: 19/141,719 - Filed: 2023-12-22 - Published: 2026-07-30 - Earliest claimed: 2022-12-22 - Assignees: The Medical College of Wisconsin, Inc. - Applicants: The Medical College of Wisconsin, Inc. - Inventors: Charles E. Hay; Jeffrey A. Medin - Web page: https://patentgrep.com/patent/US20260217851A1 ## CPC - A61P 35/00: Antineoplastic agents - C07K 16/2896: {against molecules with a "CD"-designation, not provided for elsewhere} - A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells - C07K 16/2809: {against the T-cell receptor (TcR)-CD3 complex} - A61K 2239/57: Skin; melanoma - C07K 2317/31: multispecific - C07K 2317/52: Constant or Fc region; Isotype - C07K 2317/622: Single chain antibody (scFv) - C07K 2317/64: comprising a combination of variable region and constant region components - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS - C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00) - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) ## Abstract Disclosed are bispecific single-chain constructs, pharmaceutical compositions comprising the constructs, methods of treatment using the pharmaceutical compositions, polynucleotides encoding the constructs, and methods of making the constructs. ## Claims ### Claim 1 A bispecific single-chain polypeptide construct comprising an anti-CD138 domain and an anti-CD3 domain, wherein the anti-CD138 domain comprises SEQ ID NO: 1 or a sequence with at least 85% identity to SEQ ID NO: 1. ### Claim 2 (depends on 1) The construct of claim 1, wherein the anti-CD138 domain comprises a first heavy chain and a first light chain and the anti-CD3 domain comprises a second heavy chain and a second light chain. ### Claim 3 (depends on 1) The construct of claim 1, wherein the anti-CD138 domain is SEQ ID NO: 1. ### Claim 4 (depends on 1) The construct of claim 1, wherein the anti-CD3 domain comprises SEQ ID NO: 2 or a sequence with at least 85% identity to SEQ ID NO: 2. ### Claim 5 (depends on 2) The construct of claim 2, wherein the first heavy chain comprises SEQ ID NO: 3. ### Claim 6 (depends on 2) The construct of claim 2, wherein the first light chain comprises SEQ ID NO: 4. ### Claim 7 (depends on 2) The construct of claim 2, wherein the second heavy chain comprises SEQ ID NO: 5. ### Claim 8 (depends on 2) The construct of claim 2, wherein the second light chain comprises SEQ ID NO: 6. ### Claim 9 (depends on 1) The construct of claim 1, comprising a linker. ### Claim at position 10 10-12. (canceled) ### Claim 13 (depends on 1) The construct of claim 1, comprising an antibody Fc domain. ### Claim 14 (depends on 13) The construct of claim 13, wherein the Fc domain is an IgG Fc domain. ### Claim at position 13 15-16. (canceled) ### Claim 17 (depends on 1) The construct of claim 1, wherein the construct comprises, from N to C terminus, an anti-CD138 domain, a linker, an antibody Fc domain, a linker, an anti-CD3 domain. ### Claim 18 (canceled) ### Claim 19 (depends on 1) The construct of claim 1, wherein the construct comprises SEQ ID NO: 9. ### Claim 20 (depends on 1) A pharmaceutical composition comprising the construct of claim 1 and a pharmaceutically acceptable carrier or excipient. ### Claim 21 (depends on 20) A method of treating a disease or disorder associated with CD138 expression comprising administering an effective amount of the pharmaceutical composition of claim 20 to a subject in need thereof to treat the disease or disorder. ### Claim 22 (depends on 21) The method of claim 21, wherein the disease or disorder is a cell-proliferative disease or disorder. ### Claim 23 (depends on 22) The method of claim 22, wherein the cell proliferative disease or disorder is cancer. ### Claim 24 (depends on 22) The method of claim 22, wherein the disease or disorder is multiple myeloma. ### Claim at position 22 25-30. (canceled) ### Claim 31 (depends on 1) A polynucleotide encoding the construct of claim 1. ### Claim 32 (depends on 31) A cell comprising the polynucleotide of claim 31. ### Claim at position 25 33-36. (canceled)